BioCryst Pharmaceuticals (BCRX) : Vhcp Management Ii added new position in BioCryst Pharmaceuticals during the most recent quarter end. The investment management firm now holds 4,689,435 shares of BioCryst Pharmaceuticals which is valued at $13.6 Million , the company said in a statement filed on May 13, 2016 with the SEC.BioCryst Pharmaceuticals makes up approximately 8.75% of Vhcp Management Ii’s portfolio.
Other Hedge Funds, Including , Cornerstone Capital Management Holdings. reduced its stake in BCRX by selling 317 shares or 5.02% in the most recent quarter. The Hedge Fund company now holds 6,000 shares of BCRX which is valued at $17,460. Royce Associates Lp added BCRX to its portfolio by purchasing 160,000 company shares during the most recent quarter which is valued at $465,600. Nine Chapters Capital Management sold out all of its stake in BCRX during the most recent quarter. The investment firm sold 43,600 shares of BCRX which is valued $126,876.Tiaa Cref Investment Management reduced its stake in BCRX by selling 10,844 shares or 3.21% in the most recent quarter. The Hedge Fund company now holds 326,873 shares of BCRX which is valued at $928,319.
BioCryst Pharmaceuticals (BCRX) witnessed a volatile trading activity on Wednesday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $3.4 and reached the intraday high at $3.49. The bulls started the profit booking and pushed the shares to intraday low of $3.27. The trading session was marked by a volume range of 5,87,221 shares exchanging hands. The 52-week high of the shares is $16.83 and the 52-week low is $1.63. The market cap of the company stands at $247 M and there are 7,36,92,799 shares in public circulation.
On the company’s financial health, BioCryst Pharmaceuticals reported $-0.31 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-0.23. The company had revenue of $4.80 million for the quarter, compared to analysts expectations of $5.68 million. The company’s revenue was down -29.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.21 EPS.
BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.